Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Fidaxomicin was granted FDA approval in May 2011 for the treatment of Clostridioides difficile–associated diarrhea (CDAD) in adults, which is synonymous with Clostridioides difficile infection (CDI), including initial episodes. In February 2020, the FDA broadened this approval to encompass pediatric patients aged 6 months and older with CDI. Fidaxomicin is among the limited number of antibiotics specifically approved for CDI, with its use restricted to cases where infections are confirmed or strongly suspected to be caused by C. difficile (1, 2…